California Public Employees Retirement System Has $14.69 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

California Public Employees Retirement System cut its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,217 shares of the company's stock after selling 2,948 shares during the period. California Public Employees Retirement System owned approximately 0.14% of Medpace worth $14,690,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of MEDP. R Squared Ltd bought a new stake in shares of Medpace during the 4th quarter worth about $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace in the 4th quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on MEDP shares. Robert W. Baird raised their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Mizuho dropped their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $368.30.

Medpace Stock Up 9.1 %

MEDP traded up $25.33 during trading on Wednesday, hitting $302.56. The company had a trading volume of 904,771 shares, compared to its average volume of 314,334. The company has a market capitalization of $9.15 billion, a PE ratio of 23.96, a PEG ratio of 3.81 and a beta of 1.46. The firm's 50-day moving average price is $325.79 and its 200 day moving average price is $335.08. Medpace Holdings, Inc. has a one year low of $272.00 and a one year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.